Lei Jin-Ju, Peng Rou-Jun, Kuang Bo-Hua, Yuan Zhong-Yu, Qin Tao, Liu Wen-Sheng, Guo Yun-Miao, Han Hui-Qiong, Lian Yi-Fan, Deng Cheng-Cheng, Zhang Hao-Jiong, Chen Li-Zhen, Feng Qi-Sheng, Xu Miao, Feng Lin, Bei Jin-Xin, Zeng Yi-Xin
Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Oncotarget. 2015 Sep 22;6(28):25701-14. doi: 10.18632/oncotarget.4573.
NOP14, which is functionally conserved among eukaryotes, has been implicated in cancer development. Here, we show that NOP14 is poorly expressed in breast cancer cells and invasive breast cancer tissues. In vivo and in vitro studies indicated that NOP14 suppressed the tumorigenesis and metastasis of breast cancer cells. Further investigations revealed that NOP14 enhanced ERα expression and inhibited the Wnt/β-catenin pathway by up-regulating NRIP1 expression. Survival analysis indicated that low NOP14 expression was significantly associated with poor overall survival (P = 0.0006) and disease-free survival (P = 0.0007), suggesting that NOP14 is a potential prognostic factor in breast cancer. Taken together, our findings reveal that NOP14 may suppress breast cancer progression and provide new insights into the development of targeted therapeutic agents for breast cancer.
NOP14在真核生物中功能保守，与癌症发展有关。在此，我们表明NOP14在乳腺癌细胞和浸润性乳腺癌组织中表达较低。体内和体外研究表明，NOP14抑制乳腺癌细胞的肿瘤发生和转移。进一步研究发现，NOP14通过上调NRIP1表达增强ERα表达并抑制Wnt/β-连环蛋白通路。生存分析表明，NOP14低表达与总生存期差（P = 0.0006）和无病生存期差（P = 0.0007）显著相关，提示NOP14是乳腺癌潜在的预后因素。综上所述，我们的研究结果表明NOP14可能抑制乳腺癌进展，并为乳腺癌靶向治疗药物的开发提供新见解。
